- 同花顺特色产品
- 〈高级诊股〉 全方位深度分析，提供明确投资建议
- 短期趋势：
强势上涨过程中，可逢低买进，暂不考虑做空。
- 中期趋势：
-
- 长期趋势：
已有299家主力机构披露2024-12-31报告期持股数据，持仓量总计7.23亿股，占流通A股70.39%
- 波段诊断：
-
技术面诊股
诊断结果：4.5技术面打败了85%的股票
技术面评分前10的股票
近期的平均成本为19.50元。
平均成本
近期的平均成本为19.50元。
[{"text":"\u5e73\u5747\u6210\u672c","value":"19.50","date":1743583731,"color":"0x9f0ba1"}]
市场表现
过去10个交易日，该股走势明显跑赢大盘，接近行业平均水平。
[{"date":"2025.04.03","stock":"0.88","trade":"0.45","ind":"-0.24"},{"date":"2025.04.02","stock":"-0.36","trade":"0.10","ind":"0.05"},{"date":"2025.04.01","stock":"3.07","trade":"4.61","ind":"0.38"},{"date":"2025.03.31","stock":"-0.05","trade":"-1.52","ind":"-0.46"},{"date":"2025.03.28","stock":"-0.94","trade":"-0.35","ind":"-0.67"},{"date":"2025.03.27","stock":"1.33","trade":"2.25","ind":"0.15"},{"date":"2025.03.26","stock":"-0.16","trade":"0.93","ind":"-0.04"},{"date":"2025.03.25","stock":"0.53","trade":"0.61","ind":"-0.00"},{"date":"2025.03.24","stock":"-0.42","trade":"-1.49","ind":"0.15"},{"date":"2025.03.21","stock":"-0.68","trade":"-1.36","ind":"-1.29"},{"date":"2025.03.20","stock":"-4.00","trade":"-0.68","ind":"-0.51"},{"date":"2025.03.19","stock":"0.82","trade":"-0.21","ind":"-0.10"},{"date":"2025.03.18","stock":"0.67","trade":"0.53","ind":"0.11"},{"date":"2025.03.17","stock":"0.15","trade":"0.25","ind":"0.19"},{"date":"2025.03.14","stock":"1.04","trade":"2.51","ind":"1.81"},{"date":"2025.03.13","stock":"0.84","trade":"-0.67","ind":"-0.39"},{"date":"2025.03.12","stock":"-0.31","trade":"-0.35","ind":"-0.23"},{"date":"2025.03.11","stock":"0.74","trade":"0.05","ind":"0.41"},{"date":"2025.03.10","stock":"1.06","trade":"1.54","ind":"-0.19"},{"date":"2025.03.07","stock":"-1.05","trade":"-0.69","ind":"-0.25"},{"date":"2025.03.06","stock":"0.26","trade":"1.14","ind":"1.17"}]
华润双鹤,上证指数,化学制药指数
压力支撑
该股压力位为19.39元，支撑位为19.19元。
[{"text":"\u538b\u529b\u4f4d","value":"19.39","date":1743609600,"color":"0x9f0ba1"},{"text":"\u652f\u6491\u4f4d","value":"19.19","date":1743609600,"color":"0x0b52a1"}]
多空趋势
macd
kdj
boll
asi
bias
rsi
wr
vr
资金面诊股
诊断结果：4.4资金面打败了58%的股票
主力控盘前10的股票
行业资金
化学制药行业， 近5日资金总体呈流入状态，投资者可考虑关注该行业的个股。
更新时间：04月03日 20:36
| 机构今日流向(万元) | -388.73 | 机构5日流向(万元) | 1481.80 |
| 机构10日流向(万元) | 2360.56 | 机构20日流向(万元) | -1924.35 |
机构持仓
2024-12-31 与 2024-06-30 相比，主力机构持仓量减少3357.4万股，其中基金净减仓30家，主力净减仓16家，请投资者中长期谨慎为宜。
截止2024-12-31，共299家主力机构（基金293家，一般法人2家，QFII1家，社保基金3家），持仓量总计72308.53万股，占流通A股70.39%
其中，基金持仓与2024-06-30相比：
增仓：62家 ，增持 414.73万股
减仓：92家 ，减持 2594.69万股
新出现在主力名单中：129家 ，持有3852.77万股
从主力名单中消失：145家 ，原持有3766.58万股
其中，基金持仓与2024-06-30相比：
增仓：62家 ，增持 414.73万股
减仓：92家 ，减持 2594.69万股
新出现在主力名单中：129家 ，持有3852.77万股
从主力名单中消失：145家 ，原持有3766.58万股
消息面诊股
诊断结果：6.6消息面打败了84%的股票
今日有利好新闻的公司
近期该股消息面总体多空平衡，没有较强的利好或利空趋势。
更多>>个股资讯
- 华润双鹤：4月2日获融资买入2223.74万元
2025-04-03 - 华润双鹤股价缩量调整 社保基金四季度增持动向引关注
2025-04-02 - 华润双鹤：4月1日获融资买入4083.39万元，占
2025-04-02 - 今年第二季度，11款抗肿瘤新药有望获批上市
2025-04-01 - 机构评级|中信证券给予华润双鹤“买入”评级
2025-04-01 - 华润双鹤：3月31日获融资买入2344.92万元
2025-04-01 - 一季度净利润预增138%+极端放量，减肥药龙头受关
2025-04-01 - 糖尿病“药王”易主，明星药首破20亿！扬子江、甘李
2025-03-31 - 华润双鹤：3月28日获融资买入2397.88万元
2025-03-29 - 华润双鹤：3月27日获融资买入2623.30万元，
2025-03-28
消息列表
| 利好 | 分红转增 | 10派3.71元(含税) | 2025-03-20 |
| 一般消息 | 高管变动 | 当选副总裁 | 2025-02-18 |
| 一般消息 | 重大事项 | 关联交易 | 2025-01-17 |
| 一般消息 | 高管变动 | 不再担任 | 2025-01-16 |
| 一般消息 | 高管变动 | 因工作安排原因 | 2025-01-07 |
| 一般消息 | 股东大会 | 临时股东大会 | 2024-12-27 |
| 一般消息 | 重大事项 | 关联交易 | 2024-12-27 |
| 利空 | 重大事项 | 公司违规：处罚类型 | 2024-12-10 |
| 利空 | 重大事项 | 公司违规：处罚类型 | 2024-11-28 |
| 一般消息 | 高管变动 | 不再担任 | 2024-11-12 |
| 一般消息 | 高管变动 | 公司管理团队分工调整 | 2024-09-25 |
| 利好 | 分红转增 | 10派1元(含税) | 2024-08-23 |
| 一般消息 | 高管变动 | 因工作变动原因 | 2024-08-09 |
| 一般消息 | 重大事项 | 关联交易 | 2024-05-18 |
一年消息统计
| 所有消息 | 重大消息 | 非重大消息 | |
| 利好 | 2条 | 0条 | 2条 |
| 利空 | 2条 | 0条 | 2条 |
行业面诊股
诊断结果：7.8行业面打败了99%的股票
化学制药行业最新资金流向
近10日来该行业走势不明显，明显跑赢大盘。最近120个交易日，机构评级以增持为主，认为该行业有一定投资价值。
行业走势
近10日来该行业走势不明显，明显跑赢大盘。
[{"date":"2025.04.03","price":"-0.24","value":"0.45"},{"date":"2025.04.02","price":"0.05","value":"0.10"},{"date":"2025.04.01","price":"0.38","value":"4.61"},{"date":"2025.03.31","price":"-0.46","value":"-1.52"},{"date":"2025.03.28","price":"-0.67","value":"-0.35"},{"date":"2025.03.27","price":"0.15","value":"2.25"},{"date":"2025.03.26","price":"-0.04","value":"0.93"},{"date":"2025.03.25","price":"-0.00","value":"0.61"},{"date":"2025.03.24","price":"0.15","value":"-1.49"},{"date":"2025.03.21","price":"-1.29","value":"-1.36"},{"date":"2025.03.20","price":"-0.51","value":"-0.68"},{"date":"2025.03.19","price":"-0.10","value":"-0.21"},{"date":"2025.03.18","price":"0.11","value":"0.53"},{"date":"2025.03.17","price":"0.19","value":"0.25"},{"date":"2025.03.14","price":"1.81","value":"2.51"},{"date":"2025.03.13","price":"-0.39","value":"-0.67"},{"date":"2025.03.12","price":"-0.23","value":"-0.35"},{"date":"2025.03.11","price":"0.41","value":"0.05"},{"date":"2025.03.10","price":"-0.19","value":"1.54"},{"date":"2025.03.07","price":"-0.25","value":"-0.69"},{"date":"2025.03.06","price":"1.17","value":"1.14"}]
上证指数,化学制药行业
行业排名
| 排名 | 股票名称 | 1月涨跌幅 | 5日涨跌幅 | 评分 |
|---|---|---|---|---|
| 1 | 金陵药业 | 158.11% | 2.55% | 5.5分 |
| 2 | 润都股份 | 98.98% | 39.71% | 5.0分 |
| 3 | 多瑞医药 | 65.50% | 50.00% | 4.8分 |
| 4 | 金城医药 | 54.54% | 4.96% | 5.0分 |
| 5 | 一品红 | 43.28% | 29.51% | 5.7分 |
| 6 | 哈三联 | 35.25% | 30.63% | 4.8分 |
| 8 | 翰宇药业 | 26.11% | 11.91% | 5.9分 |
| 10 | 海思科 | 24.80% | 10.82% | 6.4分 |
| 12 | 鲁抗医药 | 21.05% | 4.14% | 5.0分 |
| 14 | 科伦药业 | 19.03% | 16.25% | 5.9分 |
| 16 | 东北制药 | 16.50% | 9.58% | 5.8分 |
| 18 | 海翔药业 | 12.80% | -0.38% | 4.9分 |
| 20 | 华特达因 | 12.63% | -0.03% | 4.7分 |
| 22 | 信立泰 | 12.12% | 5.48% | 5.8分 |
| 24 | 美诺华 | 10.92% | 1.36% | 4.5分 |
| 26 | 国邦医药 | 10.51% | 3.49% | 5.4分 |
| 28 | 恒瑞医药 | 9.72% | 5.48% | 6.6分 |
| 30 | 天宇股份 | 9.40% | -2.55% | 5.3分 |
| 32 | 海正药业 | 9.15% | 5.20% | 5.7分 |
| 34 | 吉贝尔 | 8.83% | 5.46% | 5.7分 |
| 36 | 溢多利 | 8.62% | 5.45% | 5.0分 |
| 38 | 益方生物 | 8.47% | 3.27% | 5.4分 |
| 40 | 本立科技 | 8.20% | 1.61% | 5.0分 |
| 42 | 博瑞医药 | 8.14% | 3.83% | 4.7分 |
| 44 | 百济神州 | 7.87% | 8.25% | 5.9分 |
| 46 | 华邦健康 | 7.77% | 2.46% | 5.4分 |
| 48 | 华海药业 | 7.62% | -0.12% | 5.2分 |
| 50 | 天新药业 | 7.13% | 1.25% | 5.2分 |
| 52 | 辰欣药业 | 6.96% | 2.81% | 5.2分 |
| 54 | 奥锐特 | 6.85% | -1.42% | 5.0分 |
| 56 | 卫信康 | 6.56% | 1.29% | 5.2分 |
| 58 | 亿帆医药 | 6.42% | 0.34% | 5.0分 |
| 60 | 丰原药业 | 5.94% | 1.90% | 5.1分 |
| 62 | 山河药辅 | 5.58% | 1.82% | 4.7分 |
| 64 | 仙琚制药 | 5.39% | -1.45% | 4.8分 |
| 66 | 福元医药 | 5.30% | -0.06% | 5.1分 |
| 68 | 华仁药业 | 4.84% | 0.93% | 4.9分 |
| 70 | 诺泰生物 | 4.82% | -7.29% | 5.2分 |
| 72 | *ST景峰 | 4.67% | -7.19% | 4.3分 |
| 74 | 西点药业 | 4.55% | 3.82% | 5.2分 |
| 76 | 上海谊众 | 4.38% | 7.43% | 4.8分 |
| 78 | 康芝药业 | 4.03% | -0.96% | 4.1分 |
| 80 | 盟科药业 | 3.93% | 3.75% | 4.9分 |
| 82 | 健康元 | 3.61% | 1.90% | 5.1分 |
| 84 | 北大医药 | 3.40% | 0.83% | 4.8分 |
| 86 | 拓新药业 | 3.33% | 6.17% | 4.4分 |
| 88 | 新华制药 | 3.03% | 0.79% | 5.0分 |
| 90 | 华润双鹤 | 3.00% | 2.57% | 5.6分 |
| 92 | 悦康药业 | 2.56% | 1.99% | 4.6分 |
| 94 | 赛分科技 | 2.39% | 1.21% | 5.0分 |
| 96 | 广济药业 | 2.14% | -0.17% | 4.4分 |
| 98 | 海普瑞 | 2.03% | -0.52% | 5.5分 |
| 100 | 东诚药业 | 1.96% | 0.45% | 5.2分 |
| 102 | 津药药业 | 1.89% | -0.23% | 4.8分 |
| 104 | 海森药业 | 1.15% | 3.57% | 4.7分 |
| 106 | 舒泰神 | 0.67% | 2.17% | 4.3分 |
| 108 | 民生健康 | 0.52% | 0.22% | 4.3分 |
| 110 | 共同药业 | 0.00% | 2.04% | 3.8分 |
| 112 | - | 0.00% | -0.29% | 分 |
| 114 | 川宁生物 | -0.15% | 2.31% | 5.1分 |
| 116 | 泰恩康 | -0.35% | 3.08% | 4.8分 |
| 118 | 亚虹医药 | -0.59% | -0.12% | 4.4分 |
| 120 | 宏源药业 | -0.76% | 1.49% | 4.7分 |
| 122 | 奥翔药业 | -1.16% | -1.27% | 4.8分 |
| 124 | 新诺威 | -1.36% | 6.51% | 5.5分 |
| 126 | 金石亚药 | -1.72% | 0.94% | 4.0分 |
| 128 | 北陆药业 | -2.07% | 1.29% | 5.0分 |
| 130 | 微芯生物 | -2.40% | -0.16% | 4.8分 |
| 132 | 纳微科技 | -2.64% | 0.00% | 4.5分 |
| 134 | 莱美药业 | -4.27% | 1.41% | 4.3分 |
| 136 | 前沿生物 | -4.91% | 1.04% | 4.5分 |
| 138 | 东亚药业 | -5.96% | -0.81% | 3.8分 |
| 140 | 灵康药业 | -6.24% | 0.67% | 4.5分 |
| 142 | 科源制药 | -6.96% | 0.94% | 3.9分 |
| 144 | 广生堂 | -7.85% | -3.26% | 3.6分 |
| 146 | 普洛药业 | -10.00% | 0.39% | 5.7分 |
| 148 | 浙江医药 | -13.81% | -2.19% | 5.0分 |
| 150 | - | -23.69% | 0.00% | 分 |
| 152 | - | - | -38.25% | 分 |
| 154 | 河化股份 | - | 16.90% | 5.3分 |
行业评级
最近120个交易日，机构评级以增持为主，认为该行业有一定投资价值。
- 综合评级
| 研究机构 | 评级日期 | 最新评级 | 上次评级 |
| 中信证券 | 2012-09-10 | 增持 | 增持 |
| 招商证券 | 2012-09-08 | 增持 | 增持 |
| 航天证券 | 2012-09-06 | 增持 | - |
| 中银国际 | 2012-09-05 | 增持 | - |
| 齐鲁证券 | 2012-09-05 | 增持 | - |
更多>>行业资讯
- 2012-09-13亿利能源股权质押登记
- 2012-09-13太极集团修改《公司章程》
- 2012-09-13人福医药获得国家补助资金
- 2012-09-13常山药业：归还暂时用于补充流动资金的闲置募集资金
- 2012-09-13贵州百灵：公司与济南百诺医药科技开发有限公司签订技
- 2012-09-13振东制药山西省第三建筑工程公司承建山西振东泰盛制药
- 2012-09-13双成药业：战略合作框架协议进展
- 2012-09-13佛慈制药：签订推荐恢复上市、委托代办股份转让协议
- 2012-09-13昊海生科IPO资产被疑是大江股份上市募投项目
- 2012-09-13泰格医药涨势猛 业务有望快速扩张
基本面诊股
[ 截止日期：2024-12-31 ]公司经营
盈利能力：较强，高于行业平均，建议加强关注，两项指标的行业排名分别为 5/228 ， 15/228。
[{"date":"2024-12-31","value":"15.14","vol":"10.45"},{"date":"2024-09-30","value":"13.13","vol":"4.52"},{"date":"2024-06-30","value":"9.96","vol":"3.49"},{"date":"2024-03-31","value":"3.68","vol":"2.32"},{"date":"2023-12-31","value":"12.63","vol":"-2.41"}]
| 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | |
|---|---|---|---|---|---|
| 净资产收 益率(%) |
15.14 | 13.13 | 9.96 | 3.68 | 12.63 |
| 行业(%) | 10.45 | 4.52 | 3.49 | 2.32 | -2.41 |
该指标值越高，盈利能力越强，行业排名越靠前。
[{"date":"2024-12-31","value":"57.27","vol":"53.17"},{"date":"2024-09-30","value":"58.46","vol":"50.55"},{"date":"2024-06-30","value":"58.49","vol":"50.91"},{"date":"2024-03-31","value":"56.75","vol":"50.62"},{"date":"2023-12-31","value":"55.24","vol":"51.63"}]
| 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | |
|---|---|---|---|---|---|
| 销售毛利 率(%) |
57.27 | 58.46 | 58.49 | 56.75 | 55.24 |
| 行业(%) | 53.17 | 50.55 | 50.91 | 50.62 | 51.63 |
该指标值越高，盈利能力越强，行业排名越靠前。
成长能力：偏弱，与行业平均有较大差距，两项指标的行业排名分别为 19/228 ， 23/228。
[{"date":"2024-12-31","value":"-0.87","vol":"28.85"},{"date":"2024-09-30","value":"1.18","vol":"44.93"},{"date":"2024-06-30","value":"1.46","vol":"700.68"},{"date":"2024-03-31","value":"2.26","vol":"749.72"},{"date":"2023-12-31","value":"6.20","vol":"353.65"}]
| 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | |
|---|---|---|---|---|---|
| 营业收入同 比增长率(%) |
-0.87 | 1.18 | 1.46 | 2.26 | 6.20 |
| 行业(%) | 28.85 | 44.93 | 700.68 | 749.72 | 353.65 |
该指标值越高，成长能力越强，行业排名越靠前。
[{"date":"2024-12-31","value":"-2.55","vol":"94.40"},{"date":"2024-09-30","value":"1.07","vol":"-16.98"},{"date":"2024-06-30","value":"6.28","vol":"7.37"},{"date":"2024-03-31","value":"11.00","vol":"18.10"},{"date":"2023-12-31","value":"12.96","vol":"-47.20"}]
| 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | |
|---|---|---|---|---|---|
| 净利润同比 增长率(%) |
-2.55 | 1.07 | 6.28 | 11.00 | 12.96 |
| 行业(%) | 94.40 | -16.98 | 7.37 | 18.10 | -47.20 |
该指标值越高，成长能力越强，行业排名越靠前。
营运能力：较强，高于行业平均，建议加强关注，两项指标的行业排名分别为 7/228 ， 12/228。
[{"date":"2024-12-31","value":"0.70","vol":"0.51"},{"date":"2024-09-30","value":"0.53","vol":"0.33"},{"date":"2024-06-30","value":"0.38","vol":"0.23"},{"date":"2024-03-31","value":"0.18","vol":"0.12"},{"date":"2023-12-31","value":"0.68","vol":"0.44"}]
| 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | |
|---|---|---|---|---|---|
| 总资产周 转率(次) |
0.70 | 0.53 | 0.38 | 0.18 | 0.68 |
| 行业(次) | 0.51 | 0.33 | 0.23 | 0.12 | 0.44 |
该指标值越高，营运能力越强，行业排名越靠前。
[{"date":"2024-12-31","value":"3.04","vol":"3.06"},{"date":"2024-09-30","value":"2.29","vol":"2.16"},{"date":"2024-06-30","value":"1.56","vol":"1.50"},{"date":"2024-03-31","value":"0.84","vol":"0.74"},{"date":"2023-12-31","value":"2.66","vol":"2.78"}]
| 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | |
|---|---|---|---|---|---|
| 存货增长 率(次) |
3.04 | 2.29 | 1.56 | 0.84 | 2.66 |
| 行业(次) | 3.06 | 2.16 | 1.50 | 0.74 | 2.78 |
该指标值越高，营运能力越强，行业排名越靠前。
现金流能力：较强，高于行业平均，建议加强关注，两项指标的行业排名分别为 19/228 ， 15/228。
[{"date":"2024-12-31","value":"13.57","vol":"-7.38"},{"date":"2024-09-30","value":"20.16","vol":"-10.05"},{"date":"2024-06-30","value":"20.50","vol":"-254.27"},{"date":"2024-03-31","value":"10.64","vol":"-4.44"},{"date":"2023-12-31","value":"22.44","vol":"-123.06"}]
| 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | |
|---|---|---|---|---|---|
| 现金流量净额/营业收入 | 13.57 | 20.16 | 20.50 | 10.64 | 22.44 |
| 行业 | -7.38 | -10.05 | -254.27 | -4.44 | -123.06 |
该指标值越高，现金流能力越强，行业排名越靠前。
[{"date":"2024-12-31","value":"0.84","vol":"1.28"},{"date":"2024-09-30","value":"","vol":"0.00"},{"date":"2024-06-30","value":"0.57","vol":"2.18"},{"date":"2024-03-31","value":"","vol":"0.00"},{"date":"2023-12-31","value":"0.92","vol":"2.34"}]
| 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | |
|---|---|---|---|---|---|
| 资本支出／折旧和摊销 | 0.84 | - | 0.57 | - | 0.92 |
| 行业 | 1.28 | 0.00 | 2.18 | 0.00 | 2.34 |
该指标值越低，现金流能力越强，行业排名越靠前。
短期偿债能力：很强，位居行业前列,建议强烈关注，两项指标的行业排名分别为 4/228 ， 15/228。
[{"date":"2024-12-31","value":"1.87","vol":"3.03"},{"date":"2024-09-30","value":"1.59","vol":"3.65"},{"date":"2024-06-30","value":"1.46","vol":"3.58"},{"date":"2024-03-31","value":"2.61","vol":"3.74"},{"date":"2023-12-31","value":"2.42","vol":"3.71"}]
| 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | |
|---|---|---|---|---|---|
| 流动比率 |
1.87 | 1.59 | 1.46 | 2.61 | 2.42 |
| 行业 | 3.03 | 3.65 | 3.58 | 3.74 | 3.71 |
该指标值越接近2，短期偿债能力越强，行业排名越靠前。
[{"date":"2024-12-31","value":"1.41","vol":"2.45"},{"date":"2024-09-30","value":"1.19","vol":"2.91"},{"date":"2024-06-30","value":"1.07","vol":"2.88"},{"date":"2024-03-31","value":"2.08","vol":"3.08"},{"date":"2023-12-31","value":"1.85","vol":"3.01"}]
| 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | |
|---|---|---|---|---|---|
| 速动比率 |
1.41 | 1.19 | 1.07 | 2.08 | 1.85 |
| 行业 | 2.45 | 2.91 | 2.88 | 3.08 | 3.01 |
该指标值越接近1，短期偿债能力越强，行业排名越靠前。
长期偿债能力：尚可，接近行业平均，可适当关注，两项指标的行业排名分别为 15/228 ， 16/228。
[{"date":"2024-12-31","value":"33.41","vol":"32.51"},{"date":"2024-09-30","value":"34.19","vol":"33.03"},{"date":"2024-06-30","value":"34.05","vol":"33.21"},{"date":"2024-03-31","value":"22.16","vol":"33.13"},{"date":"2023-12-31","value":"23.60","vol":"33.46"}]
| 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | |
|---|---|---|---|---|---|
| 资产负债 率(%) |
33.41 | 34.19 | 34.05 | 22.16 | 23.60 |
| 行业(%) | 32.51 | 33.03 | 33.21 | 33.13 | 33.46 |
该指标值越接近50%，长期偿债能力越强，行业排名越靠前。
[{"date":"2024-12-31","value":"0.54","vol":"0.63"},{"date":"2024-09-30","value":"0.55","vol":"0.73"},{"date":"2024-06-30","value":"0.55","vol":"0.71"},{"date":"2024-03-31","value":"0.30","vol":"0.70"},{"date":"2023-12-31","value":"0.33","vol":"0.75"}]
| 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | |
|---|---|---|---|---|---|
| 产权比率 (%) |
0.54 | 0.55 | 0.55 | 0.30 | 0.33 |
| 行业(%) | 0.63 | 0.73 | 0.71 | 0.70 | 0.75 |
该指标值越高，长期偿债能力越强，行业排名越靠前。
机构评级
最近60个交易日，机构评级以买入为主，认为该股票非常值得关注。
| 研究机构 | 评级日期 | 最新评级 | 上次评级 |
| 中信证券 | 2025-04-01 | 买入 | |
| 中信建投证券 | 2025-03-31 | 买入 | |
| 华泰金融(HK) | 2025-03-26 | 买入 | |
| 华泰证券 | 2025-03-20 | 买入 |
机构预测
机构预测该股2025年每股收益与前一年相同，长期投资价值一般。
[{"date":"2021","yellowRectValue":"9.36","blueLineValue":"","type":""},{"date":"2022","yellowRectValue":"11.64","blueLineValue":"","type":""},{"date":"2023","yellowRectValue":"13.33","blueLineValue":"","type":""},{"date":"2024","yellowRectValue":"16.28","blueLineValue":"","type":""},{"date":"2025","yellowRectValue":"17.49","blueLineValue":"1.68","type":"YC"}]